Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00 at Evercore ISI

Travere Therapeutics (NASDAQ:TVTX) had its price objective lifted by Evercore ISI from $33.00 to $45.00 in a report released on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

TVTX has been the subject of a number of other research reports. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday. Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $9.00 to $27.00 in a research note on Monday, October 21st. Piper Sandler boosted their price objective on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. HC Wainwright increased their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Finally, Barclays lifted their target price on Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.77.

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $23.20 on Wednesday. The stock has a 50-day moving average price of $19.06 and a two-hundred day moving average price of $15.95. Travere Therapeutics has a 12 month low of $5.12 and a 12 month high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96.

Insider Buying and Selling

In other Travere Therapeutics news, CAO Sandra Calvin sold 15,000 shares of Travere Therapeutics stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the sale, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. The trade was a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric M. Dube sold 11,375 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total transaction of $273,455.00. Following the transaction, the chief executive officer now directly owns 419,173 shares in the company, valued at $10,076,918.92. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 218,425 shares of company stock valued at $4,674,259 over the last 90 days. Company insiders own 3.75% of the company’s stock.

Institutional Trading of Travere Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Emerald Advisers LLC boosted its holdings in Travere Therapeutics by 8.4% in the fourth quarter. Emerald Advisers LLC now owns 2,125,744 shares of the company’s stock worth $37,030,000 after acquiring an additional 165,085 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Travere Therapeutics by 6.4% during the fourth quarter. Geode Capital Management LLC now owns 1,842,301 shares of the company’s stock worth $32,100,000 after purchasing an additional 111,256 shares during the period. Finepoint Capital LP raised its position in shares of Travere Therapeutics by 0.3% during the third quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock worth $24,934,000 after purchasing an additional 5,539 shares during the period. Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Travere Therapeutics by 26.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock worth $16,588,000 after purchasing an additional 244,444 shares in the last quarter. Finally, Parkman Healthcare Partners LLC grew its position in Travere Therapeutics by 12.0% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,086,067 shares of the company’s stock valued at $15,194,000 after purchasing an additional 116,175 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.